Akari Therapeutics (AKTX) vs SeaStar Medical (ICU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SeaStar Medical (ICU) has outperformed Akari Therapeutics (AKTX) over the past year, losing 47.0% versus a loss of 80.1%. Over five years, AKTX leads with a -99.4% price change compared with -99.9% for ICU. Akari Therapeutics is the larger company by market cap ($18.6 million vs $18.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTX | ICU |
|---|---|---|
| Share price | $8.13 | $3.49 |
| Market cap | $18.58M | $18.36M |
| 1-day change | -5.74% | -6.18% |
| YTD return | -29.67% | +45.42% |
| 1-year return | -80.07% | -47.04% |
| 5-year return | -99.38% | -99.86% |
| EPS (TTM) | $0.00 | $-2.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.00 | $7.35 |
| 52-week low | $3.02 | $2.07 |
| Distance from 52-week high | -79.67% | -52.52% |
| Analyst consensus | none | none |
| Avg. price target upside | +213.65% | +186.53% |
| Average volume | 61.08K | 99.80K |
| Shares outstanding | 2.29M | 5.26M |
| Employees | 5 | 18 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ICU has outperformed AKTX by 33.0 percentage points over the past year.
About Akari Therapeutics
AKTX stock →Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
Healthcare · Biotechnology · 5 employees
About SeaStar Medical
ICU stock →SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis.
Healthcare · Biotechnology · 18 employees
AKTX vs ICU FAQ
Which is bigger, Akari Therapeutics or SeaStar Medical?
Akari Therapeutics (AKTX) is larger, with a market capitalization of $18.58M compared with $18.36M for SeaStar Medical (ICU).
Which stock has performed better over the past year, AKTX or ICU?
ICU returned -47.04% over the past 12 months, compared with -80.07% for AKTX (price return, excluding dividends). Past performance does not predict future results.
Are Akari Therapeutics and SeaStar Medical in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.